The Korean Journal of Food And Nutrition (한국식품영양학회지)

The Korean Society of Food and Nutrition (한국식품영양학회)
권호 표지
DOI QR코드

DOI QR Code

Hepatoprotective Effects of Streptococcus thermophilus LM1012 in the Methionine-Choline Deficient (MCD) Diet Induced Nonalcoholic Steatohepatitis Mice Model

  • Received : 2022.07.22
  • Accepted : 2022.10.02
  • Published : 2022.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Nonalcoholic fatty liver disease (NAFLD) is recognized one of the leading metabolic diseases globally, and the younger age population with the disease is rapidly growing, especially in developed countries. Since there has been no approved medicine, losing weight is known to be the only best remedy to control or reverse the disease. Recently, the field of microbiome has attracted much attention to offer more practical choices for patients. Here, we provide experimental evidence that Streptococcus thermophilus LM1012 (LM1012), a safe probiotic strain, is effective for improving NAFLD indexes. In the methionine-choline deficient (MCD) diet induced C57BL/6 mouse model, administration of LM1012 promoted marked reductions of aspartate transaminase (23.8%), total bilirubin (27.8%), hydroxycholesterol (64.2%), triglyceride (29.7%) and IL-1β (68.3%) compared to the MCD diet alone group. Also, the histopathological data imply that LM1012 inhibited fat accumulation and inflammation in the liver, which are the key biomarkers for progression of the disease. Together, these findings suggest that human consumption of LM1012 as a healthy nutritional supplement, may be helpful in reducing the risk of liver damages in NAFLD patients.

Keywords

Acknowledgement

This research was financially supported by Ministry of SMEs and Startups of Korea under the regional specialized industry development program (S2906501).

References

  1. Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, De La Fuente B, Gonzalez J. 2011. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: A double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 15:1090-1095
  2. Anstee QM, Goldin RD. 2006. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 87:1-16 https://doi.org/10.1111/j.0959-9673.2006.00465.x
  3. Alves-Bezerra M, Cohen DE. 2018. Triglyceride metabolism in the liver. Compr Physiol 8:1-22
  4. Barrow F, Khan S, Fredrickson G, Wang H, Dietsche K, Parthiban P, Robert S, Kaiser T, Winer S, Herman A, Adeyi O, Mouzaki M, Khoruts A, Hogquist KA, Staley C, Winer DA, Revelo XS. 2021. Microbiota-driven activation of intrahepatic B cells aggravates NASH through innate and adaptive signaling. Hepatology 74:704-722 https://doi.org/10.1002/hep.31755
  5. Cacciapuoti F, Scognamiglio A, Palumbo R, Forte R, Cacciapuoti F. 2013. Silymarin in non alcoholic fatty liver disease. World J Hepatol 5:109-113 https://doi.org/10.4254/wjh.v5.i3.109
  6. Cicero AFG, Colletti A, Bellentani S. 2018. Nutraceutical approach to non-alcoholic fatty liver disease (NAFLD): The available clinical evidence. Nutrients 10:1153 https://doi.org/10.3390/nu10091153
  7. Darnaud M, Faivre J, Moniaux N. 2013. Targeting gut flora to prevent progression of hepatocellular carcinoma. J Hepatol 58:385-387 https://doi.org/10.1016/j.jhep.2012.08.019
  8. Esposito E, Iacono A, Bianco G, Autore G, Cuzzocrea S, Vajro P, Canani RB, Calignano A, Raso GM, Meli R. 2009. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. J Nutr 139:905-911 https://doi.org/10.3945/jn.108.101808
  9. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. 2018. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 24:908-922 https://doi.org/10.1038/s41591-018-0104-9
  10. Gabr SA, Alghadir AH, Sherif YE, Ghfar AA. 2017. Hydroxyproline as a biomarker in liver disease. In Patel VB, Preedy VR (Eds.), Biomarkers in Liver Disease. pp.471-491. Springer
  11. Garcia-Tsao G, Lee FY, Barden GE, Cartun R, West AB. 1995. Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. Gastroenterology 108:1835-1841 https://doi.org/10.1016/0016-5085(95)90147-7
  12. Gillessen A, Schmidt HHJ. 2020. Silymarin as supportive treatment in liver diseases: A narrative review. Adv Ther 37:1279-1301 https://doi.org/10.1007/s12325-020-01251-y
  13. Gkolfakis P, Dimitriadis G, Triantafyllou K. 2015. Gut microbiota and non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int 14:572-581 https://doi.org/10.1016/S1499-3872(15)60026-1
  14. Horn CL, Morales AL, Savard C, Farrell GC, Ioannou GN. 2022. Role of cholesterol-associated steatohepatitis in the development of NASH. Hepatol Commun 6:12-35 https://doi.org/10.1002/hep4.1801
  15. Ikegami T, Hyogo H, Honda A, Miyazaki T, Tokushige K, Hashimoto E, Inui K, Matsuzaki Y, Tazuma S. 2012. Increased serum liver X receptor ligand oxysterols in patients with non-alcoholic fatty liver disease. J Gastroenterol 47:1257-1266 https://doi.org/10.1007/s00535-012-0585-0
  16. Jang E, Shin MH, Kim KS, Kim Y, Na YC, Woo HJ, Kim Y, Lee JH, Jang HJ. 2014. Anti-lipoapoptotic effect of Artemisia capillaris extract on free fatty acids-induced HepG2 cells. BMC Complement Altern Med 14:253 https://doi.org/10.1186/1472-6882-14-253
  17. Jeon MG, Kim TR, Lee JY, Kim HS, Ji Y, Holzapfel WH, Bae D, Choi C, Hwang YP. 2020. Hepatoprotective effects of Streptococcus thermophilus LM1012 in mice exposed to air pollutants. J Med Food 23:852-861 https://doi.org/10.1089/jmf.2019.4636
  18. Kawano Y, Cohen DE. 2013. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol 48:434-441 https://doi.org/10.1007/s00535-013-0758-5
  19. Koyama Y, Brenner DA. 2017. Liver inflammation and fibrosis. J Clin Invest 127:55-64 https://doi.org/10.1172/jci88881
  20. Kwong EK, Puri P. 2021. Gut microbiome changes in Nonalcoholic fatty liver disease & alcoholic liver disease. Transl Gastroenterol Hepatol 6:3 https://doi.org/10.21037/tgh.2020.02.18
  21. Lee SI, Lee YK, Lee IA, Choi J, Kim SD, Suh JW. 2013. Effects of mulberry leaf tea fermented by Monascus pilosus on body weight and hepatic antioxidant enzyme activities in mouse fed high-fat diet. Korean J Food Nutr 26:66-77 https://doi.org/10.9799/KSFAN.2013.26.1.066
  22. Lee S, Kwak JH, Kim SH, Jeong TB, Son SW, Kim JH, Lim Y, Cho JY, Hwang DY, Kim KS, Jung YS. 2019. Comparative study of liver injury induced by high-fat methionine- and choline-deficient diet in ICR mice originating from three different sources. Lab Anim Res 35:15 https://doi.org/10.1186/s42826-019-0016-y
  23. Lee YS, Lee DY, Kwon DY, Kang OH. 2020. Improvement effect of non-alcoholic fatty liver disease by Curcuma longa L. extract. Korean J Med Crop Sci 28:276-286 https://doi.org/10.7783/KJMCS.2020.28.4.276
  24. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, DeSimone C, Song X, Diehl AM. 2003. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37:343-350 https://doi.org/10.1053/jhep.2003.50048
  25. Machado MV, Cortez-Pinto H. 2016. Diet, microbiota, obesity, and NAFLD: A dangerous quartet. Int J Mol Sci 17:481 https://doi.org/10.3390/ijms17040481
  26. Mahzari A, Li S, Zhou X, Li D, Fouda S, Alhomrani M, Alzahrani W, Robinson SR, Ye JM. 2019. Matrine protects against MCD-induced development of NASH via upregulating HSP72 and downregulating mTOR in a manner distinctive from metformin. Front Pharmacol 10:405 https://doi.org/10.3389/fphar.2019.00405
  27. Marin V, Gazzin S, Gambaro SE, Dal Ben M, Calligaris S, Anese M, Raseni A, Avellini C, Giraudi PJ, Tiribelli C, Rosso N. 2017. Effects of oral administration of silymarin in a juvenile murine model of non-alcoholic steatohepatitis. Nutrients 9:1006 https://doi.org/10.3390/nu9091006
  28. Meroni M, Longo M, Dongiovanni P. 2019. The role of probiotics in nonalcoholic fatty liver disease: A new insight into therapeutic strategies. Nutrients 11:2642 https://doi.org/10.3390/nu11112642
  29. Miao Z, Zheng H, Liu WH, Cheng R, Lan H, Sun T, Zhao W, Li J, Shen X, Li H, Feng H, Hung WL, He F. 2022. Lacticaseibacillus paracasei K56 attenuates high-fat dietinduced obesity by modulating the gut microbiota in mice. Probiotics Antimicrob Proteins
  30. Navarro VJ, Belle SH, D'Amato M, Adfhal N, Brunt EM, Fried MW, Reddy KR, Wahed AS, Harrison S, Silymarin in NASH and C Hepatitis (SyNCH) Study Group. 2019. Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial. PLOS ONE 14:e0221683 https://doi.org/10.1371/journal.pone.0221683
  31. Neuschwander-Tetri BA, Caldwell SH. 2003. Nonalcoholic steatohepatitis: Summary of an AASLD single topic conference. Hepatology 37:1202-1219 https://doi.org/10.1053/jhep.2003.50193
  32. Nobili V, Putignani L, Mosca A, Del Chierico F, Vernocchi P, Alisi A, Stronati L, Cucchiara S, Toscano M, Drago L. 2018. Bifidobacteria and lactobacilli in the gut microbiome of children with non-alcoholic fatty liver disease: Which strains act as health players? Arch Med Sci 14:81-87 https://doi.org/10.5114/aoms.2016.62150
  33. Park EJ, Lee YS, Kim SM, Park GS, Lee YH, Jeong DY, Kang J, Lee HJ. 2020. Beneficial effects of Lactobacillus plantarum strains on non-alcoholic fatty liver disease in high fat/high fructose diet-fed rats. Nutrients 12:542 https://doi.org/10.3390/nu12020542
  34. Ramadori P, Weiskirchen R, Trebicka J, Streetz K. 2015. Mouse models of metabolic liver injury. Lab Anim 49:47-58 https://doi.org/10.1038/s41684-020-0480-x
  35. Raselli T, Hearn T, Wyss A, Atrott K, Peter A, Frey-Wagner I, Spalinger MR, Maggio EM, Sailer AW, Schmitt J, Schreiner P, Moncsek A, Mertens J, Scharl M, Griffiths WJ, Bueter M, Geier A, Rogler G, Wang Y, Misselwitz B. 2019. Elevated oxysterol levels in human and mouse livers reflect nonalcoholic steatohepatitis. J Lipid Res 60:1270-1283 https://doi.org/10.1194/jlr.m093229
  36. Rinella ME, Elias MS, Smolak RR, Fu T, Borensztajn J, Green RM. 2008. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res 49:1068-1076 https://doi.org/10.1194/jlr.M800042-JLR200
  37. Rodriguez-Romero JJ, Duran-Castaneda AC, Cardenas-Castro AP, Sanchez-Burgos JA, Zamora-Gasga VM, Sayago-Ayerdi SG. 2022. What we know about protein gut metabolites: Implications and insights for human health and diseases. Food Chem X 13:100195 https://doi.org/10.1016/j.fochx.2021.100195
  38. Runyon BA, Squier S, Borzio M. 1994. Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis. J Hepatol 21:792-796 https://doi.org/10.1016/S0168-8278(94)80241-6
  39. Sadeghipour A, Babaheidarian P. 2019. Making formalin-fixed, paraffin embedded blocks. Methods Mol Biol 1897:253-268 https://doi.org/10.1007/978-1-4939-8935-5_22
  40. Seo Y, Bazarsad D, Choe SY. 2012. Effect of Acer tegmentosum Maxim. Extracts on acute hepatitis and fatty liver in rats. J Biomed Res 13:165-170 https://doi.org/10.12729/jbr.2012.13.2.165
  41. Song Q, Zhang X. 2022. The role of gut-liver axis in gut microbiome dysbiosis associated NAFLD and NAFLD-HCC. Biomedicines 10:524 https://doi.org/10.3390/biomedicines10030524
  42. Tilg H, Moschen AR. 2010. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 52:1836-1846 https://doi.org/10.1002/hep.24001
  43. Ucar F, Sezer S, Erdogan S, Akyol S, Armutcu F, Akyol O. 2013. The relationship between oxidative stress and nonalcoholic fatty liver disease: Its effects on the development of nonalcoholic steatohepatitis. Redox Rep 18:127-133 https://doi.org/10.1179/1351000213Y.0000000050
  44. Wu Y, Li X, Tan F, Zhou X, Mu J, Zhao X. 2021. Lactobacillus fermentum CQPC07 attenuates obesity, inflammation and dyslipidemia by modulating the antioxidant capacity and lipid metabolism in high-fat diet induced obese mice. J Inflamm 18:5 https://doi.org/10.1186/s12950-021-00272-w
  45. Xiao J, Xing F, Huo J, Fung ML, Liong EC, Ching YP, Xu A, Chang RCC, So KF, Tipoe GL. 2014. Lycium barbarum polysaccharides therapeutically improve hepatic functions in non-alcoholic steatohepatitis rats and cellular steatosis model. Sci Rep 4:5587 https://doi.org/10.1038/srep05587
  46. Xie C, Halegoua-DeMarzio D. 2019. Role of probiotics in non-alcoholic fatty liver disease: Does gut microbiota matter? Nutrients 11:2837 https://doi.org/10.3390/nu11112837
  47. Yao M, Qv L, Lu Y, Wang B, Berglund B, Li L. 2021. An update on the efficacy and functionality of probiotics for the treatment of non-alcoholic fatty liver disease. Engineering 7:679-686 https://doi.org/10.1016/j.eng.2020.01.017